CA-VELODYNE-LIDAR
30.7.2020 14:02:16 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced that Emesent’s newly introduced Autonomy Level 2 (AL2) technology for Hovermap uses Velodyne lidar sensors to provide real-time perception and high-quality, accurate 3D data. Hovermap is a plug-and-play mapping and autonomy payload for industrial drones that enables autonomous flight in areas beyond visual line of sight (BVLOS) and without GPS connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200730005182/en/
The AL2 technology uses Velodyne’s Puck LITE lidar as the primary perception and mapping sensor. This allows autonomous exploration, navigation and lidar mapping in challenging inaccessible environments such as mines, civil construction works, telecommunications infrastructure and disaster response environments. As part of Emesent’s simultaneous localization and mapping (SLAM) based autonomy stack, AL2 powers drones to fly beyond communications range, self-navigate and avoid obstacles including thin wires and branches.
AL2 can be operated from take-off to landing by setting smart waypoints in a live 3D map streamed to a tablet. This allows operators to remain a safe distance from hazardous environments such as brows, stope edges, confined spaces and heights. The rich data from the Puck LITE sensor enables companies to gain better data insights on how to make mines and other environments safe.
“The Velodyne Puck LITE is simply a sensational sensor for creating drone-based mapping and autonomy solutions because of its compact size, light weight and performance – all critical for drone-mounted systems,” said Dr. Stefan Hrabar, Emesent CEO. “The sensor was an essential ingredient in helping us to create game-changing new technology that can obtain vital data in challenging environments in real time without risking the machine or operator safety.”
Emesent is an Automated with Velodyne partner at the forefront of GPS-denied drone autonomy. The company recently placed fourth in the urban circuit of the DARPA Subterranean (“SubT”) Challenge together with the Robotics and Autonomous Systems Group at the Commonwealth Scientific and Industrial Research Organization (CSIRO) and Georgia Institute of Technology.
“Emesent’s innovative use of Velodyne’s lidar sensors is helping to deliver valuable data and insights that were previously impossible to access,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “In addition to what they provide today to the mining, infrastructure, survey and mapping industries, it is exciting to consider how this innovation will help usher in a new era of autonomous drone operation across a variety of other industries.”
In the United States, the Federal Aviation Administration (FAA) currently has restrictions on drones flying beyond the visual line of sight. Emesent’s technology innovation could potentially usher in a new era of safe, autonomous drone flight – not only in mines but everywhere.
Velodyne Puck LITE sensors deliver a high-resolution image to measure and analyze indoor and outdoor environments. Designed for applications that require a sensor with a low weight and compact size, the Puck LITE delivers outstanding resolution and performance for mobile and UAV/drone applications. It provides a full 360-degree environmental view to deliver real-time 3D data.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About Emesent
Emesent is a world-leader in drone autonomy, lidar mapping and data analytics. Founded in 2018, Emesent has since built a reputation for delivering high-quality data capture in the mining, infrastructure, survey and mapping industries. Their flagship product, Hovermap, is a smart mobile scanning unit that combines advanced collision avoidance and autonomous flight technologies to map hazardous and GPS-denied environments. Hovermap is uniquely versatile, it can be handheld, drone- or vehicle-mounted to map challenging, inaccessible areas. With a wide range of applications, Hovermap is being used by customers around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005182/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom